TSH Biopharm (8432) reported revenue of NT$168.9 million for Oct 2026, +19.3% year on year and -48.1% from the previous month. Revenue for Jan–Oct 2026 was NT$1.34 billion (+19.8% year on year).
Year-on-year revenue growth: 8 months in a row. →
In Oct 2026, it ranked No. 49 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$168.9 million | +19.3% | -48.1% |
| Sep 2026 | NT$325.4 million | +34.1% | +160.8% |
| Aug 2026 | NT$124.8 million | +30.9% | +16.7% |
| Jul 2026 | NT$107 million | +26.6% | +11.1% |
| Jun 2026 | NT$96.3 million | +6.4% | -23.6% |
| May 2026 | NT$126.1 million | +34.5% | +16.3% |
| Apr 2026 | NT$108.4 million | +27.4% | -0.4% |
| Mar 2026 | NT$108.8 million | +15.6% | +55.5% |
| Feb 2026 | NT$70 million | -35.9% | -34.6% |
| Jan 2026 | NT$107 million | +27.7% | +1.3% |
| Dec 2025 | NT$105.7 million | +4.2% | -10.4% |
| Nov 2025 | NT$118 million | +28.3% | -16.7% |
| Oct 2025 | NT$141.6 million | +45.0% | -41.6% |
| Sep 2025 | NT$242.7 million | +9.0% | +154.6% |
| Aug 2025 | NT$95.3 million | +7.4% | +12.8% |
| Jul 2025 | NT$84.5 million | +9.7% | -6.6% |
| Jun 2025 | NT$90.5 million | +30.0% | -3.5% |
| May 2025 | NT$93.8 million | +3.3% | +10.2% |
| Apr 2025 | NT$85.1 million | +13.0% | -9.6% |
| Mar 2025 | NT$94.1 million | +81.0% | -13.8% |
| Feb 2025 | NT$109.2 million | +217.6% | +30.2% |
| Jan 2025 | NT$83.8 million | -26.6% | -17.3% |
| Dec 2024 | NT$101.4 million | +41.2% | +10.2% |
| Nov 2024 | NT$92 million | +44.4% | -5.8% |
| Oct 2024 | NT$97.7 million | +7.6% | -56.1% |
Jan–Oct 2026 cumulative: NT$1.34 billion (+19.8% YoY)
Other Biotech & Medical companies
Compare with peers: TSH Biopharm vs PEC / TSH Biopharm vs Lotus Pharm / TSH Biopharm vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16